近日,“阿斯利康涉骗保窝案,中国区总裁王磊配合调查”的消息不断发酵,这家知名跨国药企再度陷入多事之秋。回溯阿斯利康在全球市场最近一个周期发展,亦不过是刚刚走出低谷:2017年2月2日,阿斯利康进入“至暗时刻”。在其披露的2016年财报中,公司营收仅为213.19亿美元,同比下滑9.8%,而且这已经是阿斯利康连续第五年营收下滑。更让投资者难以接受的是,阿斯利康当时的三款核心药物Crestor(降血脂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.